MX2023000664A - Uso de antagonistas de mglur5. - Google Patents

Uso de antagonistas de mglur5.

Info

Publication number
MX2023000664A
MX2023000664A MX2023000664A MX2023000664A MX2023000664A MX 2023000664 A MX2023000664 A MX 2023000664A MX 2023000664 A MX2023000664 A MX 2023000664A MX 2023000664 A MX2023000664 A MX 2023000664A MX 2023000664 A MX2023000664 A MX 2023000664A
Authority
MX
Mexico
Prior art keywords
opioid
mavoglurant
reduction
treatment
opioid use
Prior art date
Application number
MX2023000664A
Other languages
English (en)
Inventor
Baltazar Gomez-Mancilla
Fabrizio Gasparini
Richard Carl Elciario Dolmetsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023000664A publication Critical patent/MX2023000664A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de mavoglurant, o una de sus sales farmacéuticamente aceptables: en la reducción del uso de opioides por un paciente con trastorno de uso de opioides; en la prevención de la recaída en el uso de opioides por un paciente con trastorno de uso de opioides; en la promoción de la abstinencia de opioides por un paciente con trastorno de uso de opioides; en el tratamiento de los síntomas de la depresión o ansiedad asociados con el trastorno de uso de opioides.
MX2023000664A 2020-07-17 2021-07-15 Uso de antagonistas de mglur5. MX2023000664A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053090P 2020-07-17 2020-07-17
US202063124537P 2020-12-11 2020-12-11
PCT/IB2021/056397 WO2022013809A2 (en) 2020-07-17 2021-07-15 USE OF mGluR5 ANTAGONISTS

Publications (1)

Publication Number Publication Date
MX2023000664A true MX2023000664A (es) 2023-02-27

Family

ID=76971960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000664A MX2023000664A (es) 2020-07-17 2021-07-15 Uso de antagonistas de mglur5.

Country Status (10)

Country Link
US (1) US20230270720A1 (es)
EP (1) EP4181918A2 (es)
JP (1) JP2023537844A (es)
KR (1) KR20230041006A (es)
CN (1) CN115942979A (es)
AU (1) AU2021307607B2 (es)
BR (1) BR112022025730A2 (es)
CA (1) CA3181961A1 (es)
MX (1) MX2023000664A (es)
WO (1) WO2022013809A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
JP5468608B2 (ja) 2008-08-12 2014-04-09 ノバルティス アーゲー ４−オキソ−オクタヒドロ−インドール−１−カルボサイリックアシッドメチルエステルとその誘導体の調製方法
WO2014199316A1 (en) 2013-06-12 2014-12-18 Novartis Ag Modified release formulation
PL3160464T3 (pl) * 2014-06-26 2018-12-31 Contera Pharma Aps 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych

Also Published As

Publication number Publication date
CA3181961A1 (en) 2022-01-20
JP2023537844A (ja) 2023-09-06
KR20230041006A (ko) 2023-03-23
AU2021307607A1 (en) 2022-11-17
WO2022013809A2 (en) 2022-01-20
AU2021307607B2 (en) 2024-07-04
WO2022013809A3 (en) 2022-04-14
CN115942979A (zh) 2023-04-07
US20230270720A1 (en) 2023-08-31
BR112022025730A2 (pt) 2023-01-24
EP4181918A2 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
JO2858B1 (en) Pharmaceutical dosage images
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX346186B (es) Inhibidores de proteina cinasas.
DE602005023197D1 (de) -muscarinrezeptors
EA201390823A1 (ru) ДВОЙНЫЕ ИНГИБИТОРЫ PI3 КИНАЗЫ/mTOR
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
BR112013002541A2 (pt) uso de ligante sigma, combinação de pelo menos um ligante sigma e de pelo menos um composto opióide ou opiato para administração simultânea, separada ou sequencial e método de tratamento de um paciente que sofre de oih associada à terapia opióide
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MY158522A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory diseases or condition
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
MX2020013335A (es) Metodos novedosos.
CR20210495A (es) Compuestos macrocíclicos como agonistas de sting
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2017012926A (es) Inhibidores y sus usos.
MX2023000664A (es) Uso de antagonistas de mglur5.
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
EA202191812A1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ
MA58993A1 (fr) Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий